ANTLER, ANTidepressants to prevent reLapse in dEpRessio

Phase 1

• Conditions: Depression; MedDRA version: 20.0Level: LLTClassification code 10066555Term: Chronic depressionSystem Organ Class: 100000024331; Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]

• Registration Number: EUCTR2015-004210-26-GB
• Lead Sponsor: PRIMENT Clinical Trials Unit, UC

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-04-04
• Last Update Posted: 20 July 2020

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 479

Inclusion Criteria

1)have had at least two episodes of depression
2)be aged 18-74 years (we have excluded older people as different assessments for depression are used in the older age groups)
3)be taking antidepressants for 9 months or more and currently taking: citalopram 20mg, sertraline 100mg, fluoxetine 20mg or mirtazapine 30mg
4)Satisfactory Adherence to medication
5)are considering stopping their antidepressant medication

Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 400
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 79

Exclusion Criteria

1)meet internationally agreed (ICD10) criteria for a depressive illness
2)have bipolar disorder, psychotic illness, dementia, alcohol or substance dependency, or a terminal illness
3)are not able to complete self-administered questionnaires in English
4)have contraindications for any of the prescribed medication
5)pregnancy or intention to get pregnant within the next 12 months
6) use of monoamine oxidase inhibitors
7) allergies to placebo excipients
8) Current enrolment in another CTIMP

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified